bevacizumab,panitumumab
amgen,roche,takeda,medsir
['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva', 'medsir']
great talk by dr. yoshino on ph 3 paradigm trial assessing mfolfox6 + panitumumab (anti-egfr) or bevacizumab (anti-vegf) -left-sided os: 37.9 vs 34.3 months (hr 0.82) -panitumumab + mfolfox6 as a new potential paradigm for 1l treatment of ras wild-type left-sided mcrc
#asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc